Latest News Releases From The Newsroom
Splunk, ePlus and LiveRamp Beat Estimates, Digital Turbine Falls Short
May 24th, 2023
Splunk Inc. (Nasdaq: SPLK), a leading provider of data analytics and monitoring solutions, has released its financial results for the fiscal first quarter of 2024. The company reported non-GAAP earnings per share (EPS) of $0.18, significantly b. Read more
Financial Results Triggering Stock Surges: VNET Group, NVIDIA, Modine Manufacturing, e.l.f. Beauty, Nutanix, Zuora
May 24th, 2023
VNET Group, Inc. (Nasdaq: VNET) has announced its financial results for the first quarter of 2023, exceeding market expectations. The company reported earnings per share (EPS) of $0.06, while the consensus projected a loss of $0.09 per share. This po. Read more
Disappointing Results in Mirati Therapeutics' SAPPHIRE Study and Annexon's ARCHER Trial Lead to Stock Declines
May 24th, 2023
Mirati Therapeutics, Inc. (Nasdaq: MRTX) revealed disappointing news regarding the SAPPHIRE study, as it failed to meet its primary goal of overall survival in the final analysis. The Phase 3 study aimed to assess the effectiveness of sitravatinib, i. Read more
Statement Regarding the Termination of Boston Scientific Corporation’s Attempted Acquisition of a Majority Stake in M.I. Tech Co., Ltd.
May 24th, 2023
Washington D.C. / CRWE PRESS RELEASE / May 24, 2023 - In response to the announcement that Boston Scientific Corporation and non-vascular stent manufacturer M.I. Tech Co., Ltd. have terminated their $230 million purchase agreement, Federal. Read more
NVIDIA Down Before Earnings; Textron, Wave Life Sciences and Shopify Downgraded
May 24th, 2023
NVIDIA Corporation (Nasdaq: NVDA) is scheduled to announce its financial results for the first quarter of fiscal-year 2024 on Wednesday after the closing bell. Market participants are eagerly awaiting this announcement to gain insights into the compa. Read more
Enveric Biosciences Soars on EVM201 Series Potential, Immutep Surges on Clinical Trial Findings, Buy Rating for IDEAYA Biosciences
May 24th, 2023
Enveric Biosciences, Inc. (Nasdaq: ENVB) said that has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another patent application involving its EVM201 Series The soon-to-issue patent, titled "C4-Carbox. Read more
Analysts' Perspective: Palo Alto Networks' PT Raised, Agilent Technologies' PT Lowered
May 24th, 2023
Palo Alto Networks, Inc. (Nasdaq: PANW) has seen a series of upward adjustments in its price target from various financial institutions. Deutsche Bank raised the price target from $210 to $225, Scotiabank increased it from $212 to $222, and Raymond J. Read more
Upgrades and Price Target Adjustments for Berry Global, Sherwin-Williams, Owens Corning, Organogenesis, and Workday
May 24th, 2023
In the latest market updates, several companies have received upgrades in their ratings and price targets. Berry Global Group, Inc. (NYSE: BERY) has been upgraded from Hold to Buy, with its price target raised from $69 to $73 at Truist. In pre-. Read more
Abercrombie & Fitch Beats Estimates, GigaCloud Technology Achieves Record Profitability, XPeng's Q1 Falls Short, and Autodesk Gets Market Perform Rating
May 24th, 2023
Abercrombie & Fitch Co. (NYSE: ANF) has released its first-quarter fiscal 2023 earnings results. The company reported adjusted earnings per share (EPS) of $0.39, surpassing the consensus estimate of a loss of $0.05 per share. This positive performanc. Read more
Market Buzz: Palo Alto Networks, Urban Outfitters, and Inovio See Pre-Market Upswing on Positive Financials and Medical Breakthrough
May 24th, 2023
Palo Alto Networks, Inc. (Nasdaq: PANW) published its financial results for the third quarter of fiscal year 2023, with adjusted earnings per share of $1.10, outperforming the consensus estimate of $0.93. The company also provided forward-looking gui. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026




Member Login